We're using our first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders.
Location: United States, California, San Diego
Total raised: $73M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | RA Capital... | racap.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 30.04.2018 | Series C | $63M | - |
| 20.07.2016 | Series B | $10M | RA Capital... |
Mentions in press and media 15
| Date | Title | Description |
| 01.04.2024 | Впервые в мире почку свиньи изменили генетически и пересадили человеку. Теперь их можно массово пересаживать... | Хирурги из США провели человеку трансплантацию почки, полученной из генетически модифицированной свиньи. СМИ сообщают, что данная операция является прорывом в области ксенотрансплантации, когда органы, клетки или ткани пересаживаются из одн... |
| 13.07.2018 | George Golumbeski's first stop out of Celgene: Grail; Roivant taps Genentech vet Myrtle Potter for operations role | → Three months after quietly slipping out the back door at Celgene, George Golumbeski has taken up the president role at the cancer detection startup Grail in a similarly discreet manner. The former BD chief — noted for ... |
| 30.04.2018 | Startup developing semi-synthetic protein therapies raises $63M to tame IL-2 | In the near term, Synthorx is leveraging this technology to tame interleukin-2 (IL-2). Arguably the first immunotherapy, IL-2 boosts the effector T-cells that destroy cancer, offering some patients the opportunity to be cured. Unfortunately... |
| 30.04.2018 | Synthorx Announces $63M Series C Funding | SAN DIEGO, CA, Synthorx Inc. announced today the completion of a $63 million Series C financing, led by OrbiMed. >> Click here for more funding data on Synthorx >> To export Synthorx funding data to PDF and Excel, click here... |
| 30.04.2018 | Synthorx Raises $63M in Series C Financing | Synthorx Inc., a La Jolla, Calif.-based biotechnology company using synthetic biology to discover and develop novel protein therapeutics, completed a $63m Series C financing. The round was led by OrbiMed and joined by new investors, Medicxi... |
| 20.07.2016 | Synthorx Announces $10M Series B Funding | SAN DIEGO, CA, Synthorx Inc. announced today the completion of a $10 million Series B financing, led by RA Capital Management. >> Click here for more funding data on Synthorx >> To export Synthorx funding data to PDF and Exc... |
| 20.07.2016 | Synthorx Raises $10M | San Diego-based Synthorx, a developer of protein therapeutics technology, said it has raised $10M in a Series B financing this morning. The funding was led by RA Capital Management, and also included Avalon Ventures and Correlation Ventures... |
| 20.07.2016 | RA Capital Leads $10M Series B for Synthorx | Synthorx Inc. announced today the completion of a $10 million Series B financing, led by RA Capital Management and joined by Series A investors Avalon Ventures and Correlation Ventures. In conjunction with the financing, Andrew Levin, M.D.,... |
| 20.07.2016 | Synthorx Completes $10M Series B Financing | Synthorx Inc., a La Jolla, Calif.-based biotechnology company using synthetic biology to discover and develop novel protein therapeutics, completed a $10m Series B financing. The round was led by RA Capital Management with participation fro... |
| 20.07.2016 | Synthorx receives $10M to pivot toward treatments | The influx of capital will fund a significant evolution at Synthorx, which has been focused on validating their synthetic biology technology. The additional resources will allow them to begin developing treatments, pivoting from a platform ... |
Show more